Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yourgene Offers Premaitha An Asian Reprieve From Illumina Patent Tussle

Executive Summary

Noninvasive prenatal testing specialist Premaitha Health has agreed to acquire Taiwan's Yourgene Bioscience, enabling the UK company to expand its presence in Asia. The deal also offers an important market that has not been tainted by ongoing patent litigation between Premaitha and US next-generation sequencing firm Illumina.

You may also be interested in...



M&A Analysis: Underwhelming 2016, But Hope For 2017 US Market Boom

The last month of 2016 saw a final flurry of medtech M&A activity as companies rushed to seal deals before the New Year arrived. Medtech Insight's M&A data tracker recorded twice as many deals in December compared to the previous month, but that was not enough to boost the year's tally, which fell behind 2015.

Premaitha pushing on in spite of Illumina prenatal testing patent lawsuit

UK noninvasive prenatal testing specialist Premaitha Health has been dealt a blow after larger rival Illumina sued it for patent infringement. But while Premaitha CEO Stephen Little described the development as a “nuisance,” he is confident that the firm’s technology does not infringe any third-party IP, he told Clinica.

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel